A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)

Summary

Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced may mean the cancer has spread to nearby or other parts of the body. The cancer may not be able to be treated with surgery or radiation, which uses beams of intense energy (like X-rays) to shrink or get rid of tumors. Some cancers may not have gone away or came back after previous treatment. MK-2010, the trial treatment, is designed to help the immune system fight cancer.

This trial will look at MK-2010 when given with another trial treatment called sacituzumab tirumotecan (sac-TMT). Sac-TMT is an antibody-drug conjugate (ADC). An ADC attaches to specific targets on cancer cells and delivers treatment to destroy those cells.

The goals of this trial are to learn:

* About the safety of MK-2010 with sac-TMT and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems.
* How many participants who receive MK-2010 with sac-TMT have the cancer respond to treatment. Respond means the cancer gets smaller or goes away.

Conditions

• Advanced Solid Tumors
• Malignant Neoplasm

Interventions

BIOLOGICAL

MK-2010

Administered as an intravenous (IV) infusion

BIOLOGICAL

Sacituzumab tirumotecan

Administered as an IV infusion

DRUG

Histamine H1 Receptor Antagonist

Administered as a premedication per the approved product label

DRUG

Histamine H2 Receptor Antagonist

Administered as a premedication per the approved product label

DRUG

Acetaminophen (or equivalent)

Administered as a premedication per the approved product label

DRUG

Dexamethasone (or equivalent)

Administered as a premedication per the approved product label

DRUG

Steroid mouthwash (dexamethasone or equivalent)

Administered orally per the approved product label as a rescue medication

DRUG

Epinephrine

Administered for emergency use per the approved product label

Sponsors & Collaborators

• Merck Sharp & Dohme LLC

  lead INDUSTRY

Principal Investigators

• Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-09-30

Primary Completion

2031-09-30

Completion

2031-09-30

FDA Drug

Yes